A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis

Haque, Emily; Azhar, Aaminah; Corbett, John; Frieder, Jillian; Wang, Xuan; Menter, Alan

doi:10.1007/s13555-020-00436-1

Cited by 5 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the diet-induced obesity animal model, infliximab led to a reduction in the levels of blood glucose and insulin, and restored glucose homeostasis [57]. Surprisingly, patients with psoriasis with concomitant overweight or obesity are more likely to sustain the long-term response to infliximab than patients with normal weight for at least 5 years in a real-world study [58]. The dose of etanercept, adalimumab, and certolizumab pegol in the therapy of psoriasis is fixed, and their efficacy and safety are impaired by obesity.…”

Section: Tnf-α Inhibitorsmentioning

confidence: 97%

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

Jiang

Chen

et al. 2023

BioDrugs

View full text Add to dashboard Cite

Psoriasis is a systemic immune-mediated disease associated with an increased risk of comorbidities, such as psoriatic arthritis, cardiovascular disease, metabolic syndrome, inflammatory bowel disease, psychiatric disorders, and malignancy. In recent years, with the advent of biological agents, the efficacy and safety of psoriasis treatments have dramatically improved. Presently, tumor necrosis factor-α inhibitors, interleukin-17 inhibitors, interleukin-12/23 inhibitors, and interleukin-23 inhibitors are approved to treat moderate-to-severe psoriasis. Small-molecule inhibitors, such as apremilast and deucravacitinib, are also approved for the treatment of psoriasis. Although it is still unclear, systemic agents used to treat psoriasis also have a significant impact on its comorbidities by altering the systemic inflammatory state. Data from clinical trials and studies on the safety and efficacy of biologics and small-molecule inhibitors provide important information for the personalized care and treatment for patients with psoriasis. Notably, treatment with interleukin-17 inhibitors is associated with new-onset or exacerbations of inflammatory bowel disease. In addition, great caution needs to be taken when using tumor necrosis factor-α inhibitors in patients with psoriasis with concomitant congestive heart failure, multiple sclerosis, and malignancy. Apremilast may induce weight loss as an adverse effect, presenting also with some beneficial metabolic actions. A better understanding of the characteristics of biologics and small-molecule inhibitors in the treatment of psoriasis comorbidities can provide more definitive guidance for patients with distinct comorbidities.

show abstract

Section: Tnf-α Inhibitorsmentioning

confidence: 97%

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

Jiang

Chen

et al. 2023

BioDrugs

View full text Add to dashboard Cite

show abstract

“…In addition, obesity makes the body enter a immunodepressive state, losing the normal immune response. 40 A retrospective multicenter study conducted in Italy reported that the mean PASI of the group with obesity with psoriasis was significantly higher than that of the non-obese group, and seemed to be related to the disease severity and the lower response to secukinumab. 41 Singh et al 42 also discovered that the treatment failure rate of anti-TNF therapy in patients who were overweight/ obese was 60% higher than that in normal cases, and even patients with obesity treated via weight-based regimens (such as infliximab) had an inferior response to therapy.…”

Section: Relationship Between Psoriasis and Obesity And Its Relevance...mentioning

confidence: 99%

“…Obesity changes the pharmacokinetics of drugs and increases the drug clearance, thus resulting in a shortened half-life and reduced serum concentration. In addition, obesity makes the body enter a immunodepressive state, losing the normal immune response 40 . A retrospective multicenter study conducted in Italy reported that the mean PASI of the group with obesity with psoriasis was significantly higher than that of the non-obese group, and seemed to be related to the disease severity and the lower response to secukinumab 41 .…”

Section: Relationship Between Psoriasis and Obesity And Its Relevance...mentioning

confidence: 99%

The Association of Psoriasis and Obesity: Focusing on IL-17A-Related Immunological Mechanisms

et al. 2021

Int J Dermatol Venereol

View full text Add to dashboard Cite

Psoriasis is a chronic, recurrent, inflammatory skin disease that is often accompanied by obesity. An increasing amount of research has elucidated the pathophysiological link between psoriasis and obesity. Since 2005, interleukin (IL)-17-producing T helper 17 cells and their main effector cytokine IL-17A have been considered to play a critical role in the pathogenesis of psoriasis; the marked effect of biotherapies targeting IL-17A on moderate and severe psoriasis has further established its role in psoriasis. Recent studies have found that obesity induces T helper 17 cells to secrete IL-17A and participate in the pathogenesis of psoriasis. IL-17A may be a crucial element in the association between psoriasis and obesity. This review discusses the association between psoriasis and obesity, with a focus on and the implications regarding the need to treat psoriasis.

show abstract

“…137,164 Infliximab, another TNF inhibitor, has also been shown to be effective in the treatment of paediatric psoriasis. [193][194][195][196] Infliximab is administered via intravenous infusion. 194 The recommended dose is 5 mg/kg at weeks 0, 2, and 6 and every 8 weeks thereafter.…”

Section: Fumaric Acid Estersmentioning

confidence: 99%

Childhood guttate psoriasis: an updated review

Leung,

Barankin,

Lam

et al. 2023

DIC

View full text Add to dashboard Cite

Background Guttate psoriasis is common and affects 0.5–2% of individuals in the paediatric age group. This review aims to familiarize physicians with the clinical manifestations, evaluation, diagnosis and proper management of guttate psoriasis. Methods A search was conducted in July 2023 in PubMed Clinical Queries using the key term “guttate psoriasis”. The search strategy included all observational studies, clinical trials and reviews published within the past 10 years. The information retrieved from the search was used in the compilation of the present article. Results Guttate psoriasis typically presents with an abrupt onset of numerous, small, scattered, tear-drop-shaped, scaly, erythematous, pruritic papules and plaques. Sites of predilection include the trunk and proximal extremities. There may be a history of preceding streptococcal infection. Koebner phenomenon is characteristic. Guttate psoriasis may spontaneously remit within 3–4 months with no residual scarring, may intermittently recur and, in 40–50% of cases, may persist and progress to chronic plaque psoriasis. Given the possibility for spontaneous remission within several months, active treatment may not be necessary except for cosmetic purposes or because of pruritus. On the other hand, given the high rates of persistence of guttate psoriasis and progression to chronic plaque psoriasis, some authors suggest active treatment of this condition. Conclusion Various treatment options are available for guttate psoriasis. Triggering and exacerbating factors should be avoided if possible. Topical corticosteroids alone or in combination with other topical agents (e.g. tazarotene and vitamin D analogues) are the most rapid and efficient treatment for guttate psoriasis and are therefore the first-line treatment for mild cases. Other topical therapies include vitamin D analogues, calcineurin inhibitors, anthralin, coal tar and tazarotene. Ultraviolet phototherapy is the first-line therapy for moderate-to-severe guttate psoriasis, as it is more practical than topical therapy when treating widespread or numerous small lesions. Systemic immunosuppressive and immunomodulatory therapies (e.g. methotrexate, cyclosporine, retinoids, fumaric acid esters and biologics) may be considered for patients with moderate-to-severe guttate psoriasis who fail to respond to phototherapy and topical therapies.

show abstract

A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis

Cited by 5 publications

References 38 publications

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

The Association of Psoriasis and Obesity: Focusing on IL-17A-Related Immunological Mechanisms

Childhood guttate psoriasis: an updated review

Contact Info

Product

Resources

About